Clinical Tech Leader @clinicaltechleader.bsky.social · 01/10/2026The clinical research organizations that benefit most from AI will not be those with the most tools; they will be the ones with clean data, adaptable governance, and a human accountable for every consequential decision. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 29/09/2026Biostatisticians do far more than analyze results at the end of a trial. Their design-stage input determines whether the protocol, data collection, and analysis can answer the clinical question in the first place. Bringing them in late is not efficiency. It is avoidable risk. 011
Clinical Tech Leader @clinicaltechleader.bsky.social · 28/09/2026Compliance failures at scale are rarely fixed by asking people to try harder. This artilce shows what happens when an institution builds the infrastructure behind compliance: ownership, workflows, tracking, education, accountability, and patience for adoption. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 24/09/2026AI can make clinical operations more predictive, not just more automated. The opportunity is using clean, validated operational data to forecast enrollment, staffing, and site-performance risk early enough to change the outcome before a study falls behind. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 22/09/2026Two planning gaps can quietly derail a clinical program: no clear target product profile and a rushed dose or population decision before Phase 3. The common cause is failing to bring enough cross-functional expertise in early, while the cost of correcting course is still manageable. 000
Clinical Tech Leader @clinicaltechleader.bsky.social · 21/09/2026Before buying another clinical research platform, map the workflow it is meant to support. Technology can accelerate a defined process. It cannot compensate for unclear ownership, undocumented exceptions, or teams that operate differently by default. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 17/09/2026A coordinator should not have to serve as the connection between 12 systems during a patient visit. The real opportunity in clinical trial technology is not another platform. It is interoperability that gives staff more time for patients and study execution. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 15/09/2026Digital twins may help reduce sample size or improve trial efficiency within randomized studies, but using them as a substitute for a real control arm is a different proposition; one that requires evidence the model has reduced, not concealed, the uncertainty randomization is designed to address. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 14/09/2026Clinical data quality is an ownership problem as much as a technology problem. The people who understand the downstream need for clean data must have a voice before the protocol is finalized, not after preventable problems are already embedded in the study. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 10/09/2026Clinical research cannot build a sustainable workforce if people have to discover the profession by accident. Formal recognition, earlier awareness, apprenticeships, and clearer entry pathways are infrastructure for trial delivery, not simply HR initiatives. 020
Clinical Tech Leader @clinicaltechleader.bsky.social · 08/09/2026The next RWE breakthrough may already be in data an organization owns. AI can help find the pattern. The bottleneck is having enough clinical and analytical capacity to determine whether the pattern is real, meaningful, and actionable. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 03/09/2026Technology reduces site burden when it supports the site’s workflow. It creates burden when the same patient data must be entered again in a sponsor-mandated system. Duplicate entry is a quality and enrollment problem, not just a workflow annoyance. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 27/08/2026Clinical trial interoperability is not mainly a technical problem. The standards and capabilities exist. The real barriers are incentives, switching costs, and the lack of a forcing function strong enough to make open systems the better business decision. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 24/08/2026Most remote-monitoring vendor conversations start with AI. They should start earlier. This checklist covers the questions that determine whether wearable trial data is trustworthy before it reaches the analytics layer: hardware, timing, connectivity, power, validation, and training. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 20/08/2026Responsible AI in clinical research is not just about adopting tools. It requires better user training, thoughtful governance, and transparency about failures, not only success stories. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 17/08/2026AI can help identify anomalies in decentralized trial data, but it cannot recover a signal that was captured poorly, mistimed, or lost in transmission. Before asking whether a platform is AI-enabled, ask whether its data foundation is trustworthy. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 13/08/2026Decentralized technology is only patient-centric if it reduces the work patients actually experience. The question before adding a wearable or digital tool isn’t just what it can measure. It’s what it replaces. 000
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 13/08/2026Decentralized trials reduce burden only when they replace something. A wearable that eliminates the need for a site visit helps. One added to an already packed protocol may create more work for patients. Before adding tech, ask: what does it replace? www.clinicaltechleader.com/doc/decentra...clinicaltechleader.comDecentralized Trials Promised Less Burden. Did They Deliver?Wearables and other technology to facilitate decentralized trials were supposed to ease patient burden. Elisa Cascade explains why the results depend entirely on design. 121
Clinical Tech Leader @clinicaltechleader.bsky.social · 10/08/2026Wireless connectivity in decentralized trials is a data integrity problem, not simply an IT concern. Packet loss, interference, and battery tradeoffs can determine whether device data is complete and trustworthy. Connectivity belongs in scientific vendor diligence. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 06/08/2026This piece challenges how we evaluate clinical AI. A single accuracy score isn’t enough. We need evidence that models perform across different populations, sites, devices, and workflows. Portability testing should be part of every AI vendor diligence process. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 04/08/2026This is the second piece in a series decentralized trial data quality. The first focused on the analog layer. This one tackles timestamp drift and synchronization across multiple sensors. If your trial correlates ECG, SpO2, or other signals, timing integrity matters as much as sensor accuracy. 011
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 04/08/2026Accurate sensors aren’t enough. If timestamps drift across devices, multi-sensor trial data becomes unreliable. Synchronization is a blind spot in decentralized trials. Data quality isn’t just about the signal. It’s about the signal and the time. www.clinicaltechleader.com/doc/the-sync...clinicaltechleader.comThe Synchronization Problem Clinical Research Isn't WatchingWhy timestamp drift between wearable sensors quietly undermines decentralized trial data, and why almost no one is asking about it. 011
Clinical Tech Leader @clinicaltechleader.bsky.social · 30/07/2026In ophthalmology trials, the bottlenecks aren’t just about integration. They’re about image-heavy data, reading-center workflows, and physically constrained staffing. If your platform can’t handle that, it’s not ready for specialty indications. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 27/07/2026This piece challenges a common assumption in clinical research tech: we focus on software and AI, but data quality is often determined earlier, at the sensor level. If signal capture is flawed, everything downstream is compromised. 011
Clinical Tech Leader @clinicaltechleader.bsky.social · 23/07/2026This is one of the clearest takes on a persistent issue in clinical research: we’ve digitized workflows but not connected them, leaving coordinators to reconcile systems instead of focusing on patients. Before adding more AI or automation, we need to fix interoperability and workflow design. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 15/07/2026Tech can work as designed and still fail in reality. The real test isn’t the demo; it’s a coordinator explaining an app to a tired patient or a rater squeezing one more assessment into a visit. When it fails there, you see missing data, deviations, slow enrollment, and patients opting out. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 10/07/2026"Technology at Versiti exists to make sure the right information reaches the right person in time to matter. Everything else – the RFP processes, the security classifications, the careful pacing on AI adoption – is in service of that one goal." 010
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 02/07/2026“Design with them, not just for them.” If your sites helped choose and test your trial tech — and were paid for that time — how different would their day-to-day burden look? www.clinicaltechleader.com/doc/site-tec... 011
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 30/06/2026“Pay or pay.” Either sponsors invest upfront in reducing site burden, or they pay later in delayed enrollment and burned-out coordinators. Where are you currently underpaying on site burden and overpaying on recruitment pain? www.clinicaltechleader.com/doc/paying-s... 011
Clinical Tech Leader @clinicaltechleader.bsky.social · 26/06/2026Interesting question, and an even more interesting answer. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 24/06/2026Joe has a lot of interesting things to say here. Check it out! 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 22/06/2026It seems that this shouldn't need to be said, but here we are ... 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 17/06/2026Got two minutes, 12 seconds? Find out why the real problem with managing clinical trial tech stacks is broader than eSource and why sponsors should integrate around the systems sites already use. www.clinicaltechleader.com/doc/why-site... 000
Clinical Tech Leader @clinicaltechleader.bsky.social · 15/06/2026The takeaway is pretty clear: the tech stack problem was never just about the technology. It’s about protocol quality, incentives, and whether sponsors and sites are actually designing workflows together. Until those align, adding more tools moves the friction around instead of removing it. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 11/06/2026Integration isn’t a technical problem; it’s a negotiation problem. If the value isn’t clear on both sides, the answer will always be no. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 09/06/2026"If sites are already building workarounds to survive the sponsor’s tech stack, then the stack itself is what needs to change. The real question is not whether sites can keep up; it’s whether sponsors are willing to stop creating unnecessary work for them." 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 03/06/2026Clinical trial tech should simplify work, not add friction. This conversation digs into what it really takes to make the stack work for sites, sponsors, and trials. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 27/05/2026It's not too late to get started, but it's getting close! 010
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 26/05/2026If you're interested in the FDA's RTCT initiative, check out this look at what demands will be placed on your tech stack. TL/DR: If you want to be positioned for the pilot or broader adoption that follows, you're already behind if you haven't started. www.clinicaltechleader.com/doc/what-rea...clinicaltechleader.comWhat Real-Time Clinical Trials Demand From Your Tech StackRTCT requires continuous data flow, AI governance, and real-time coordination. Here’s what the infrastructure shift actually demands, and where the current industry falls short. 021
Reposted by Clinical Tech LeaderISPOR @ispor.bsky.social · 20/05/2026Check out highlights from #ISPORAnnual in Philadelphia! --> www.linkedin.com/feed/update/...linkedin.com#isporannual #heor #healthcare #healthpolicy #rwe #hta #marketaccess #patients | HEOR ConferencesIt’s a wrap! ISPOR 2026 concluded today with a closing keynote, delivered by John G. Singer, Founder and Executive Director of Blue Spoon Consulting, that offered a perspective on the future of the he... 032
Clinical Tech Leader @clinicaltechleader.bsky.social · 20/05/2026“You only get one chance to make a first impression. RTCT may get data to FDA faster, but faster is only better if what you’re sending is clean, contextualized, and agreed upon in advance.” – Tala Fakhouri, @parexel.bsky.social l 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 20/05/2026Happy Clinical Trials Day to the clinical development and clinical operations professionals, working hard behind the scenes! 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 14/05/2026If the industry’s benchmark for AI success is cycle time reduction, it will get exactly that and miss something far more significant in the process. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 12/05/2026Still seeing this play out across trials—alignment, not innovation, is the real bottleneck. Worth a closer look if you're working with digital endpoints. 020
Clinical Tech Leader @clinicaltechleader.bsky.social · 11/05/2026This is the shift people still underestimate: digital endpoints aren’t waiting on validation anymore—they’re waiting on organizations to catch up. The real challenge now is cross-functional alignment, not scientific proof. 020
Clinical Tech Leader @clinicaltechleader.bsky.social · 04/05/2026Great read. Clinical data quality isn’t something you “fix” at the end anymore; in modern trials, it has to be managed continuously, with risk-based focus on the data that actually drives decisions. 010
Reposted by Clinical Tech LeaderJohn Oncea @buck25.bsky.social · 04/05/2026Clinical trials have more tech than ever, so why is site burden rising? Join @clinicaltechleader.bsky.social to explore the real issue: not innovation, but alignment. Featuring experts from Tufts CSDD, Keenova & Dauntless. Free to attend 👉 event.on24.com/wcc/r/531746... 021
Clinical Tech Leader @clinicaltechleader.bsky.social · 01/05/2026This is the shift everyone saw coming but didn’t plan for. Sites aren’t just end users anymore — they’re becoming builders. The question now isn’t if BYOT scales, it’s who defines the rules before it does. 010
Clinical Tech Leader @clinicaltechleader.bsky.social · 27/04/2026That’s not a training problem. That’s an architecture problem. 000
Clinical Tech Leader @clinicaltechleader.bsky.social · 24/04/2026Looking forward to more use of digital twins, and SaaMD is an exciting prospect, too. 010
